TY - JOUR
T1 - Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection
AU - Ricciardi, Michael J.
AU - Rust, Lauren N.
AU - Nuria, Pedreño Lopez
AU - Yusova, Sofiya
AU - Biswas, Sreya
AU - Webb, Gabriela M.
AU - Gonzalez-Nieto, Lucas
AU - Voigt, Thomas B.
AU - Louw, Johan J.
AU - Laurino, Fernanda D.
AU - DiBello, John R.
AU - Raué, Hans Peter
AU - Barber-Axthelm, Aaron M.
AU - Chun, Kimberly
AU - Uttke, Samantha
AU - Raphael, Lidiane M.S.
AU - Yrizarry-Medina, Aaron
AU - Rosen, Brandon C.
AU - Agnor, Rebecca
AU - Gao, Lina
AU - Labriola, Caralyn
AU - Axthelm, Michael
AU - Smedley, Jeremy
AU - Julander, Justin G.
AU - Bonaldo, Myrna C.
AU - Walker, Laura M.
AU - Messaoudi, Ilhem
AU - Slifka, Mark K.
AU - Burton, Dennis R.
AU - Kallas, Esper G.
AU - Sacha, Jonah B.
AU - Watkins, David I.
AU - Burwitz, Benjamin J.
N1 - Publisher Copyright:
Copyright © 2023 The Authors,
PY - 2023/3/29
Y1 - 2023/3/29
N2 - Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distribution difficulties leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South America. To establish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccinated humans and identified two capable of potently neutralizing multiple pathogenic primary YFV isolates. Using both hamster and nonhuman primate models of lethal YFV infection, we demonstrate that a single administration of either of these two potently neutralizing antibodies during acute infection fully controlled viremia and prevented severe disease and death in treated animals. Given the potential severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing YFV cases during outbreaks.
AB - Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distribution difficulties leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South America. To establish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccinated humans and identified two capable of potently neutralizing multiple pathogenic primary YFV isolates. Using both hamster and nonhuman primate models of lethal YFV infection, we demonstrate that a single administration of either of these two potently neutralizing antibodies during acute infection fully controlled viremia and prevented severe disease and death in treated animals. Given the potential severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing YFV cases during outbreaks.
UR - http://www.scopus.com/inward/record.url?scp=85151222828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151222828&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.ade5795
DO - 10.1126/scitranslmed.ade5795
M3 - Article
C2 - 36989376
AN - SCOPUS:85151222828
SN - 1946-6234
VL - 15
JO - Science translational medicine
JF - Science translational medicine
IS - 689
M1 - eade5795
ER -